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Abstract: Growth factors play important roles in tissue regeneration. However, because of 
their  instability  and  diffusible  nature,  improvements  in  their  performance  would  be 
desirable for therapeutic applications. Conferring binding affinities would be one way to 
improve their applicability. Here we review techniques for conjugating growth factors to 
polypeptides with particular affinities. Conjugation has been designed at the level of gene 
fusion and of polypeptide ligation. We summarize and discuss the designs and applications 
of binding growth factors prepared by such conjugation approaches. 




Growth factors are involved in the regulation of a variety of cellular processes and typically act as 
signaling molecules between cells. They promote cell proliferation, differentiation and maturation, 
which vary in  growth factors. As a result, they play important roles in wound healing and tissue 
regeneration [1]. However, most growth factors act in a diffusible manner and are generally unstable in 
a tissue environment. This prolonged retention is considered to maintain the activity of growth factors 
in cells or in their environment (i.e., the extracellular matrix [ECM] or artificial implant scaffolds) and 
to be advantageous in regenerative medicine applications, until the repair process is initiated or even 
completed. Thus, many attempts have been made to improve the performance of growth factors (e.g., 
their active period and stability). In addition, it is very important to add biofunctionality such as the 
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regulation of cell functions to biomaterials used for artificial organs [2]. Modification of growth factors 
for immobilization on, or for high-affinity binding to cells or scaffold biomaterials has been performed 
by various researchers. 
2. Diffusible and Nondiffusible Actions of Growth Factors 
In designing growth factors for tissue engineering, regenerative medicine, and cell culture systems, 
it is important to consider their mechanisms of action at the cellular and molecular levels. Figure 1 
summarizes the modes of action of growth factors in cells. Diffusible interactions (e.g., endocrine, 
paracrine, autocrine and intracrine) and nondiffusible interactions (e.g., juxtacrine and matricrine) are 
known to occur. It is also known that each growth factor does not necessarily have a single mechanism 
of action at the cellular level. 
Figure 1. Modes of action of growth factors. Growth factors interact with their receptors in 
a diffusible manner (e.g., by endocrine, paracrine, autocrine and intracrine pathways) or in 
a nondiffusible manner (e.g., by juxtacrine and matricrine pathways). Some growth factors 
are known to act in both ways. 
 
Most growth factors which act in a diffusible manner, interact with their cognate receptor on the 
cell membrane, and form a complex. This interaction induces phosphorylation of the receptor and 
triggers signal transduction in the cell. These complexes are then internalized, partially decomposed by 
lysosomes, and partially recycled to the cell membrane. Thus, internalization of the receptor/growth 
factor  complexes  leads  to  the  desensitization  of  cells  (downregulation),  and  to  the  reduction  of 
excessive  responses  and  overstimulation.  In  contrast,  some  growth  factors  are  known  to  act  in  a 
nondiffusible manner by being present at the cell surface (juxtacrine) or by associating with specific 
substances,  such  as  the  ECM  (matricrine).  The  nondiffusible  mechanism  was  elucidated  by  the 
discovery of cell membrane-bound growth factors in the 1990s [3,4], which include heparin-binding 
EGF-like  growth  factor  (HB-EGF),  transforming  growth  factor-β  (TGFβ),  tumor  necrosis  factor-α 
(TNFα), colony stimulating factor 1 (CSF1), and the c-kit ligand. These growth factors are barely 
internalized even after binding to their receptors but exhibit long-term activity without downregulation. 
This point suggests the possibility of designing binding growth factors with specific activities [5]. Int. J. Mol. Sci. 2012, 13  6055 
 
 
It is recognized that there are three important elements in tissue regeneration: cells, matrix and 
growth  factors  (Figure  2).  Conjugating  the  latter  two  elements  would  enable  cells  to  reconstitute 
damaged tissues stably and efficiently during regeneration. The regulation of each element is important 
in regenerative medicine or tissue engineering. 
Figure  2.  Three main factors in  tissue engineering:  cells,  growth factors and matrices 
(scaffolds). The conjugation of growth factors and matrices provides a new approach for 
generating biofunctional substrates for regenerative medicine. 
 
Figure 3. Preparation of binding growth factors by genetic fusion or enzymatic peptide 
ligation methods. Whereas the genetic fusion method has been used in most studies of 
binding growth factors, the peptide ligation approach can be used for binding peptides 
containing noncanonical residues such as phosphorylated amino acids. 
 
Here  we  describe  two  ways  of  designing  conjugated  growth  factors:  one  is  genetic  fusion  to 
combine natural polypeptides and the other is peptide ligation to combine natural polypeptides (usually 
growth  factors)  and  nonnatural  polypeptides  containing  noncanonical  amino  acids  (usually  
target-binding peptides) (Figure 3). The genetic approach has been developed since recombinant DNA 
technology arose. On the other hand, the peptide ligation method was developed to compensate the Int. J. Mol. Sci. 2012, 13  6056 
 
 
solid  phase  synthesis  of  biological  macromolecules  such  as  oligonucleotides,  oligopeptides,  and 
oligosaccharides. Because of the length of macromolecules prepared by solid phase synthesis, it was 
necessary to elongate them by chemical or enzymatic methods. Various methodologies have been 
studied using bioorthogonal chemistry [6]. 
Table 1. Gene-engineered binding growth factors which bind to biological and organic materials. 





TGFβ1 [7,8], EGF [9], bFGF 
[10], BMP3 [11]  
CBD polypeptide 
a  
(10 amino acids) 
vWF 
EGF [12], bFGF [13]  CBD (20 kDa)  Bacterial 
collagenase 
PDGF [14], bFGF[15], 
BMP2 [16], NGF [17], 
BDNF [18], EGF [19], 
VEGF [20], NT3 [21] 
CBD polypeptide 
b  
(7 amino acids) 
Human 
collagenase 
EGF [22], HGF [23],  
VEGF [24] 
CBD (40 or 27 kDa)  Fibronectin 
Fibrin 
Fibrinogen 
NGF [25], BMP2 [26],  
KGF [27],VEGF [28,29,30], 
ephrin B2 [31], IGF-I [32] 
FXIIIa substrate 
sequence 




EGF [33]  FBD (11 kDa)  Fibronectin 
Cell (integrin)  EGF [34], bFGF [35]  Cell-binding domain (30 
kDa) 
Fibronectin 
EGF [36,37]  Cell adhesive sequence 
d  Fibronectin 
Cell (integrin and 
IGF-I receptor) 
IGF-I [38]  Vitronectin (full size)  Vitronectin 
Artificial 
substrate 
Solid surface  EGF [39,40], LIF [41],  
HGF [42] 
Fc region  Immunoglobulin 










Key:  BDNF,  brain-derived  neurotrophic  factor;  bFGF,  basic  fibroblast  growth  factor;  BMP,  bone 
morphogenetic  protein;  CBD,  collagen-binding  sites  or  domain;  EGF,  epidermal  growth  factor;  FBD, 
fibronectin fibrin-binding domain; FXIIIa, activated coagulation factor XIII; HGF, hepatocyte growth factor; 
IGF-I, insulin-like growth factor; IGF-IR, insulin-like growth factor-I receptor; IGFBP4, insulin-like growth 
factor-binding  protein  4;  KGF,  keratinocyte  growth  factor;  LIF,  leukemia  inhibitory  factor;  NGF,  nerve 
growth factor; NT3, neurotrophin-3; PDGF-BB, platelet-derived growth factor BB (homodimer); SCF, stem 
cell  factor;  TGFβ,  transforming  growth  factor  β;  VEGF,  vascular  endothelial  growth  factor;  vWF,  von 
Willebrand factor. Peptide sequences: 
a WREPSFMALS; 
b TKKTLRT; 




f (APGVGV)n or (GVGVP)n. 
3. Designs Based on Genetic Fusion 
Much knowledge about the interactions between biological molecules and biological substrates has 
accumulated. Based on this knowledge, peptide sequences for binding to targets were selected and 
used for fusion with growth factors as listed in Table 1. These binding growth factors were produced 
as chimeric proteins by recombinant expression from DNA sequence encoding growth factors and Int. J. Mol. Sci. 2012, 13  6057 
 
 
target-binding peptides (Figure 3). Growth factors have been developed that bind not only to biological 
substrates such as collagen or cells, but also to artificial substrates such as plastics or metals. Although 
most of the target-binding peptides were portions of natural proteins, nonnatural polypeptide sequences 
were also employed. 
3.1. Collagen-Binding Growth Factors 
There are many examples of binding growth factors with collagen affinity. Because collagen is the 
major  component  of  the  ECM  and  is  present  in  most  tissues,  it  is  a  most  promising  target  for 
therapeutic applications. To date, four kinds of polypeptide sequences from the collagen-binding site 
or domain (CBD) of different proteins have been employed to generate the collagen-binding growth 
factor:  von  Willebrand  factor  (vWF,  10  amino  acids),  bacterial  collagenase  (~24  kDa),  human 
collagenase (eight amino acids), and fibronectin (~40 kDa or 27 kDa). Gene sequences encoding these 
polypeptide  sequences  and  those  encoding  growth  factor  sequences  were  fused  and  expressed  by 
recombinant techniques as single proteins. 
Nimni and his colleagues produced a fusion protein of the CBD from vWF with TGFβ1 or other 
growth factors [7–11]. Although recombinant human collagen-binding TGFβ1 (rhTGFβ1-F2) had a 
lower biological activity compared with its native counterpart [7], when combined with a collagen gel, 
rhTGFβ1-F2 stimulated the migration and proliferation of mesenchymal stem cells in the gel, as well 
as their differentiation to cartilage cells [8]. Other fusion proteins of epidermal growth factor (EGF, 
EGF-CBD)  [9],  basic  fibroblast  growth  factor  (bFGF,  rhbFGF-F2)  [10],  and  bone  morphogenetic 
protein3 (BMP3, rhBMP3-C) [11] were also reported; all showed binding affinity to collagen and an 
activity similar to that of the original molecule. 
Nishi  et  al.  produced  other  fusion  proteins  using  the  collagen-binding  motif  from  bacterial 
collagenase  fused  to  EGF  or  bFGF  [12].  Both  products  were  retained  for  about  one  week  when 
subcutaneously injected into rats, suggesting their tight binding to collagen or other ECM components. 
The EGF fusion protein exhibited only 1/10  of the original EGF activity, while the bFGF fusion 
protein showed an activity similar to that of the native molecule. The CBD might affect the activity of 
the fusion protein or the binding affinity to the receptor, depending on the growth factors being fused. 
Brewster  et  al.  employed  the  same  CBD  to  generate  collagen-binding  bFGF  (R136K-CBD)  [13]; 
R136K is an engineered bFGF that has thrombin resistance. The binding affinity of the fusion protein 
was four times that of native bFGF and R136K. It is not clear if this  modified molecule has any 
advantage over the native one, considering that bFGF itself has very high affinity to collagen. 
A  short  polypeptide  sequence  of  the  human  collagenase  CBD  was  also  employed  to  construct 
collagen-binding fusion proteins of platelet-derived growth factor BB (PDGF-BB) [14], bFGF [15], 
BMP2  [16],  nerve  growth  factor  (NGF)  [17],  brain-derived  neurotrophic  factor  (BDNF)  [18],  
EGF  [19],  VEGF  (vascular  endothelial  growth  factor)  [20]  and  neurotrophin-3  [21].  Zhao  et  al. 
compared a short polypeptide sequence of vWF with that of human collagenase as the fusion partner 
for bFGF and found that the latter provided a higher binding affinity to collagen [15]. 
We have also designed collagen-binding growth factors by a fusion of the fibronectin CBD with 
growth factors; CBD-EGF [22], CBD-HGF (HGF = hepatocyte growth factor) [23], CBD-VEGF [24], 
CBD-PDGF-BB  (unpublished)  and  CBD-BMP4  (unpublished).  These  fusion  proteins  exhibited Int. J. Mol. Sci. 2012, 13  6058 
 
 
binding affinity to major collagen types I–V, which was not observed for the native growth factors. 
Moreover,  they  showed  authentic  biological  activities  in  the  collagen-bound  state.  These  fusion 
proteins  can be  stored for longer periods than native growth factors without  loss of their activity 
(Figure  4).  The  fused  CBD  moiety  might  protect  the  growth  factor  moieties  from  degradation  or 
denaturation. 
Figure 4. Stability of the growth-stimulating activity of collagen-binding epidermal growth 
factor (EGF). Fresh proteins or proteins stored at 4 ° C for 30 days in culture medium (left 
graph) or bound to collagen-coated wells (right graph) were applied to cultures of human 
dermal fibroblasts (48-well plates). Filled columns, day 0; open columns, day 30. Cell 
growth activity was evaluated at seven days of culture using a WST1 colorimetric assay 
(absorbance at 450–650 nm; mean ±  SD). Similar results were obtained for CBD-HGF 
(CBD = collagen-binding sites, HGF = hepatocyte growth factor) 
 
3.2. Fibrin-Binding Growth Factors 
Fibrin is an abundant protein present on the surface of injured tissues. In addition, it has been 
studied as a material for tissue engineering scaffolds. Therefore, growth factors with fibrin-binding 
affinity are considered useful for tissue regeneration. Sakiyama-Elbert et al. produced a fusion protein 
between  NGF  and  a  short  polypeptide  of  the  α2-plasmin  inhibitor  (α2-PI)  [25];  the  activated 
coagulation factor XIII (FXIIIa, also known as plasma transglutaminase) mediated the cross-linking of 
this  sequence  to  fibrin.  In  addition,  a  plasmin  cleavage  sequence  was  inserted  between  the  α2-PI 
sequence and the growth factor. The resulting fusion protein (TG-P-NGF) was incorporated into fibrin 
clots by FXIIIa and was then released by plasmin when the tissues started to heal. TG-P-NGF was 
designed to be released ―when cells demand.‖ The activity of the fusion protein was approximately 
40% of that of native NGF, when assayed by neurite extension in PC12 cells. Unlike collagen-binding 
growth factors, this fusion protein bound to fibrin covalently. This could be related to the reduced 
activity observed in an in vitro assay. 
The  same  or  similar  construct  designs  were  applied  to  BMP2  [26],  keratinocyte  growth  factor 
(KGF)  [27],  VEGF  [28–30],  ephrin  B2  [31]  and  insulin-like-growth  factor-I  (IGF-I)  [32].  The 
elevation of alkaline phosphatase activity in C3H10T1/2 cells mediated by the fibrin-binding BMP2 
was similar to that observed for native BMP2, whereas its retention in a fibrin gel was more than that 
of the native protein (60% vs. 25% of added amount). The KGF fusion protein bound to fibrin gel and Int. J. Mol. Sci. 2012, 13  6059 
 
 
promoted the growth of epithelial cells after release from the gel. VEGF121 is a VEGF isoform that 
lacks the fibrin-binding sequence found in the major isoform (VEGF165) [30]. Fusion with the α2-PI 
sequence  enabled  the  incorporation  of  VEGF121  into  a  fibrin  gel.  In  addition,  the  fusion  protein 
stimulated the growth of endothelial cells on the gel in a dose-dependent manner. 
We  produced  another  fibrin-binding  growth  factor:  a  chimeric  protein  of  the  fibronectin  
fibrin-binding domain (FBD) and EGF [33]. This fusion protein (FBD-EGF) bound to fibrin in the 
absence of the cross-linking enzyme (FXIIIa) and might be suitable for the preparation of fibrin-based 
scaffolds with EGF activity. The wound-healing potential of FBD-EGF was examined using an in vitro 
culture  model  of  keratinocyte  sheets;  repair  of  the  injured  sheet  was  enhanced  by  fibrin-bound  
FBD-EGF but not by EGF alone. 
3.3. Cell-Binding Fusion Proteins 
Cell-binding growth factors have been designed to bind cell surface molecules such as integrins and 
receptors. The cell-binding domain of fibronectin (~30 kDa, including the RGD sequence that binds to 
integrins)  was  employed  to  produce  EGF  fusion  protein  (C-EGF)  [34]  or  bFGF  fusion  protein  
(FN-FGF) [35]; proliferation of rat kidney fibroblasts or human umbilical vein endothelial cells was 
stimulated. However, their efficacy was not clearly shown. These fusion proteins might not be retained 
on the culture plates for long periods. An improved cell-binding EGF (containing an RGD sequence) 
was  generated  via  the  incorporation  of  hydrophobic  linker  sequences  [36]  and  collagen-binding 
sequences [37] that ensured retention on culture substrate. 
Van Lonkhuyzen et al. produced a chimeric protein of IGF-I and vitronectin (VN). This protein 
(VN: IGF-I) is associated with IGF-I-binding protein (IGF-BP) [38]. The complex of VN: IGF-I and 
IGF-BP  bound  to  both  the  IGF-I  receptor  and  to  integrin,  stimulated  receptor-mediated  and  
integrin-mediated  pathways.  As  a  result,  the  VN:  IGF-I/IGF-BP  complex  exhibited  a  higher  cell 
proliferation activity than the IGF-I/IGF-BP complex. Although the authors mainly emphasized the 
role of cross-talk in IGF-I receptor-mediated signaling and integrin-mediated signaling, vitronectin 
also seemed to contribute to cell adhesion via adsorption of the fusion protein to the substrate. 
3.4. Organic Material-Binding Growth Factors 
Growth factors have also been engineered to bind to artificial materials. Ogiwara et al. produced an 
EGF fusion protein coupled with the Fc region of immunoglobulin G (IgG) [39]. The Fc region is 
often used as  a fusion tag to  allow extracellular domains  of large membrane proteins  or receptor 
molecules to adhere nonspecifically to solid surfaces, thanks to its hydrophobicity [40]. Their fusion 
protein EGF-Fc was able to adsorb stably to tissue culture-treated surfaces, and mouse fibroblast Swiss 
3T3 cells adhered to an EGF-Fc-coated surface. Phosphorylation of EGF receptors and the subsequent 
activation of mitogen-activated protein kinase (MAPK) were induced by the adsorbed EGF-Fc. MAPK 
activation  was  sustained  even  after  4  h,  suggesting  that  EGF-Fc  activated  MAPK  signaling 
continuously without internalization of the growth factor. The Fc region was also fused to leukemia 
inhibitory factor (LIF) [41]. Mouse embryonic stem cells maintained their undifferentiated state on 
LIF-Fc-coated surfaces. A fusion protein of Fc region and HGF also induced continuous activation of 
Akt signaling [42]. Int. J. Mol. Sci. 2012, 13  6060 
 
 
Artificial polypeptide sequences were also employed to generate binding growth factors. An elastin-
like polypeptide consisting of (APGVGV)n or (GVGVP)n repeated sequences was used for binding to 
hydrophobic  solid  surfaces.  The  hydrophobicity  of  these  peptide  sequences  could  be  altered  in  a 
thermosensitive manner; they showed hydrophilicity and detached from hydrophobic substrates below 
the  phase  transition  temperature.  Elloumi  et  al.  produced  fusion  proteins  of  EGF  and  elastin-like 
peptide containing an RGD cell-binding sequence for enhancing cell adhesion [36,37]. Minato et al. 
fused  an  elastin-like  peptide  with  IGF-binding  protein  4  (IGF-BP4)  and  succeeded  in  promoting 
cardiomyocyte differentiation in mouse embryonic stem cells [43]. On the other hand, Doheny et al. 
fused the cellulose-binding domain of bacterial xylanase with the extracellular domain of stem cell 
factor (SCF) [44]. The fusion construct bound to cellulose tightly and stimulated the proliferation of 
SCF-dependent murine and human cells. 
3.5. Titanium-Binding Growth Factors  
Titanium  is  the  metallic  biomaterial  most  widely  used  for  artificial  joints  and  dental  implants. 
Titanium is highly suitable for clinical use because of its high biocompatibility, good mechanical 
properties and excellent corrosion resistance. In addition, dental implants made of titanium can form 
tight adhesions between the titanium surface of implants and bone tissue (termed osseointegration). 
However, it takes as long as several weeks for osseointegration and patients have to wait for a longer 
period to complete recovery. Therefore, surface modification of titanium, including protein coating for 
improving biocompatibility and osseointegration is important to shorten the recovery period. However, 
it is generally difficult to modify the metal surface directly with biological molecules. To overcome 
this  problem,  high-throughput  selection  methods  such  as  phage  display,  yeast  display,  ribosomal 
display or mRNA display have been developed. Phage display in particular was developed around 
1990 and employed for the selection of peptides binding to inorganic substrates including BaTiO3 for 
electronic  applications,  SiO2,  TiO2,  aluminum,  steel,  semiconductors,  platinum,  silver  and 
hydroxyapatite  [45–60].  These  are  summarized  in  Table  2.  Typically,  phage  display  technologies 
introduce a combinatorial library (of the order of 10
9 sequences) of 7-mer or 12-mer peptide sequences 
to a molecule, ligand or material. The technique has been utilized to identify amino acid sequences that 
recognize specific substrates, serving as a strategy to create biological linkers to bridge biomolecules 
and  synthetic  materials  at  the  nanoscale.  The  selected  peptides  are  called  peptide  aptamers  (from 
―aptus‖ in Latin, the term was used for selected oligonucleotides for the first time). 
Table 2. List of inorganic material-binding peptides found by phage display. 
Peptide sequence  Binding target  References 
HQPANDPSWYTG/NTISGLRYAPHM  BaTiO3  46 
CRRWESKRC  SiO2  47 
CTKRNNKRC/CHKKPSKSC  TiO2  47 
VPSSGPQDTRTT  Aluminum/steel  48 
CNNPMHQNC/VISNHAESSRRL/SLTPLTTSHLRS  Semiconductor  49–51 
PTSTGQA/CPTSTGQAC  Platinum  52 
AYSSGAPPMPPF  Silver  53,54 
YDSRSMRPH  ZnO  55 Int. J. Mol. Sci. 2012, 13  6061 
 
 
Table 2. Cont. 
Peptide sequence  Binding target  References 
CGPRHTDGLRRIAARGPC  Cu2O  56 
RRTVKHHVN  Fe2O3  57 
RKLPDAPGMHTW  TiO2/Si/Ag  58 
SVSVGMKPSPRP  Hydroxyapatite and tooth enamel  59 
VTKHLNQISQSY  Hydroxyapatite and bone-like minerals  60 
Kashiwagi et al. fused BMP2 with an oligopeptide aptamer sequence to make Ti-binding peptide-1 
(TBP-1) that has an affinity to titanium [61]. This peptide aptamer sequence was selected using a 
phage display system [58]. The fusion of this sequence allowed the reversible binding of BMP2 to 
titanium, with retention of its biological activity. However, they found that fusion of proteins with this 
peptide reduced its affinity to a TiO2 surface, and considered that intramolecular interactions between 
the peptide aptamer and the BMP moiety affected the binding affinity. 
To avoid this problem, we recently constructed a new selection system consisting of a random 
peptide library fused with the EGF sequence to make a TiO2-binding EGF, using a ribosomal display 
system (unpublished). In this system, DNA sequences encoding both random sequence peptides and 
EGF were subjected to the selection system. Through this selection method, we expected to enhance 
the affinity to TiO2 surfaces modulated by intramolecular interactions between the growth factor and 
the binding portion. A peptide sequence fused with EGF (A8-EGF) was obtained after several rounds 
of selection, and its affinity to TiO2 surfaces and effects on cell proliferation were evaluated. The 
binding affinity of A8-EGF to TiO2 was higher than that of TBP-1 fused to EGF. This selection 
method appeared to reduce the possibility of conformational changes in binding growth factors, by 
fusing a random peptide library to growth factors ahead of selection. A8-EGF synthesized by a solid 
phase method also showed a high affinity to TiO2 after protein refolding. To evaluate the enhancement 
of cell proliferation, NIH3T3 cells were cultured in the presence of A8-EGF for two days and the  
rate of cell proliferation was estimated. A8-EGF itself enhanced cell proliferation as much as  did 
unmodified EGF in the soluble state. This selection technology extends the possibility of designing 
binding growth factors. 
4. Designs Based on Peptide Ligation 
In parallel with progress in gene technology, chemical or enzymatic approaches for the synthesis of 
biological macromolecules have also progressed with the development of the Merrifield method [62]. 
The  oligonucleotides  and  oligopeptides  that  are  synthesized,  have  contributed  significantly  to 
biological and medical science and technology. Recent developments in the pharmaceutical industry 
require the large-scale production of biological macromolecules as drugs. However, although solid-
phase  methods  have  realized  the  practical  synthesis  of  oligonucleotides,  oligopeptides  and 
oligosaccharides, the chain lengths achieved have been limited. Therefore, similar to oligonucleotide 
ligation,  some  ligation  methods  including  native  chemical  ligation  have  been  developed  for 
polypeptide chain extension to increase the chain length [63]. 
Ligation methods have also enabled us to synthesize more complicated macromolecules, and it has 
become a useful method in bioorthogonal chemistry, as shown in Figure 5 [64–70]. We can now Int. J. Mol. Sci. 2012, 13  6062 
 
 
prepare many types of complex macromolecules, including new synthetic polymer–biomacromolecular 
conjugates and biologically processed biomacromolecules. The former types include the conjugation 
of biological macromolecules with polyethylene glycol or stimuli-responsive polymers for medical or 
bioindustrial applications [71–77]. The latter molecules are biological modifications of DNA, RNA, or 
polypeptides.  Therefore,  it  is  now  possible  that  growth  factors  and  affinity  peptides  carrying 
noncanonical  amino  acids  can  be  prepared  separately  and  enzymatically  conjugated  into  a  single 
protein (Figure 3). To our knowledge, the design of a binding growth factor using this approach is the 
only example reported to date [78]. 
Figure 5. Methodology of bioorthogonal chemistry. Chemical ligation, enzymatic ligation, 
and genetic incorporation are included. 
 
One example is hydroxyapatite (HA) binding to BMP by conjugation with an active site of protein 
having affinity to tooth surfaces [78]. HA is well known as a bone implant material [79,80], because of 
its  composition,  similar  to  natural  bone.  The  salivary  gland  protein  statherin  has  an  affinity  to  
HA  [81,82]  and  chemically  synthesized  short  peptides  designed  from  this  protein  have  been  
reported [83]. In these, consecutive noncanonical amino acids—phosphorylated serines (pSpS)—were 
responsible for the affinity. Therefore, it was necessary to bind these noncanonical amino acids to 
BMP to prepare the HA-binding BMP. For this preparation, an enzymatic peptide ligation method was 
employed as shown in Figure 6. Soluble human BMP4 (hBMP4) with an enzymatic reaction target 
sequence at the C-terminal end was initially produced as fusion protein with maltose-binding protein 
(MBP)  using  an  Escherichia  coli  expression  system.  For  the  enzymatic  ligation,  sortase  A,  a 
transpeptidase produced by Staphylococcus aureus to anchor cell surface proteins to the cell wall [84] 
was  employed.  The  construct  recognized  short  motifs  of  the  amino  acid  sequence  LPXTG  at  the  
C-terminal of one polypeptide and a GG sequence at the N-terminal of the other polypeptide. It then 
cleaved the peptide bond of the former peptide between its threonine and glycine followed by the Int. J. Mol. Sci. 2012, 13  6063 
 
 
formation of an amide bond to the latter peptide. This unique reaction has been utilized extensively for 
peptide ligation [85–87]. Because of the shortness of recognized peptide sequences, ligation by sortase 
A is likely to minimize the influence of the added sequences to any resulting proteins. After a peptide 
sequence  containing  phosphorylated  serine  (GGGpSpSH6)  was  synthesized  chemically,  these  two 
polypeptides were ligated by sortase A reaction, and then the MBP moiety was removed by Factor Xa. 
The resulting conjugated growth factor (hBMP4-pSpS) was purified using a histidine tag. An hBMP4 
conjugate containing canonical serines (hBMP4-SS) was prepared similarly to the control to compare 
the HA-binding affinity. 
Figure  6.  Scheme  of  the  production  and  purification  of  hydroxyapatite-binding  bone 
morphogenetic protein (BMP). Using a sortase reaction, a peptide carrying noncanonical 
amino  acids  (pSpS)  was  fused  with  the  protein  MBP-hBMP4  bearing  a  recognition 
sequence. After cleavage of the maltose-binding protein (MBP) moiety with Factor Xa, 
hBMP4-pSpS was isolated by His tag affinity. 
   
Both  hBMP4-pSpS  and  hBMP4-SS  bound  to  HA-beads  in  concentration-dependent  manner  as 
measured by an anti-BMP4 antibody binding within the range examined (0–2 g/mL). The amount of 
bound hBMP4-pSpS was significantly higher than that of hBMP4-SS at each concentration examined. 
These data confirmed that the pSpS sequences were  responsible for the enhanced HA binding of 
hBMP4-pSpS. To confirm the biological activity of the HA-bound BMP4 conjugate, multipotential 
C3H10T1/2 mesenchymal cells were seeded onto the HA beads with hBMP4-pSpS as described [88]. 
The expression levels of osteogenic genes (osteocalcin and osteopontin) known as markers of bone 
physiology [89] were enhanced in the cells after one week of culture. Protein-untreated beads and 
hBMP4-SS-treated beads  induced osteocalcin  and osteopontin expression within similar  but  lower 
ranges.  This  enhancement  of  the  marker  expression  levels  showed  that  hBMP4-pSpS  retained 
authentic BMP4 activity after HA binding and that the increased binding of hBMP4-pSpS enhanced 
the osteogenic differentiation of C3H10T1/2 cells. Int. J. Mol. Sci. 2012, 13  6064 
 
 
5. Application of Engineered Binding Growth Factors 
The binding growth factors were designed to continue to stimulate signaling for a long time. This 
advantage was the result of substantial immobilization to natural tissues or to artificial scaffolds by 
simple addition. Therefore, their usefulness has been studied with regard to their efficacy in wound 
healing, tissue reconstruction and substitution. 
5.1. Wound Healing 
Collagen is exposed upon tissue injury. Thus, wound surfaces are considered to be good target sites 
for collagen-binding growth factors. CBD-EGF and CBD-HGF were retained on the wound surfaces 
and promoted closure in intractable skin wounds of diabetic (db/db) mice [22,90]. Implantation of a 
collagen  sponge  combined  with  CBD-EGF  on  skin  wounds  induced  epithelialization  above  or 
underneath the sponge. Similar effects were observed for other collagen-binding factors such as bFGF 
(rhbFGF-F2, in  collagen solution) [8] and PDGF-BB (combined with a collagen membrane) [91]. 
Fibrin-binding KGF (P-KGF) in combination with fibrin showed a potential for wound healing of 
human skin tissues grafted to athymic mice [27], although its efficacy was marginal compared with 
that of native KGF/fibrin. Collagen-binding growth factors were also applied to other wounded tissues, 
such as the colon destroyed by inflammation [9] and blood vessels injured and deprived of endothelial 
layer by a balloon catheter [90,92]. Restoration of the epithelial and endothelial layers was enhanced 
by the fused collagen-binding growth factors. 
5.2. Repair of Cardiovascular Tissues by Implants 
The angiogenic factors VEGF, bFGF and HGF have been studied for their therapeutic potential to 
restore the blood supply in ischemic tissues. The effects of gene-engineered constructs of these factors 
were also studied. Fibrin-binding VEGF121 (α2PI1-8-VEGF121) mixed with fibrin exhibited efficacious 
angiogenic properties. In a chorioallantoic membrane assay, the blood vessel density was ~1.5 times 
higher with fibrin-binding VEGF121 than that induced by native VEGF121. In addition, α2PI1-8-VEGF121 
induced the formation of nonleaky vessels on a polytetrafluoroethylene chamber coated with fibrin and 
implanted subcutaneously [29]. 
Collagen-binding  HGF  (CBD-HGF)  enhanced  blood  vessel  migration  into  subcutaneously 
implanted collagen sponges that were combined with the fusion protein [23]. Endothelialization of the 
implanted  collagen  material  prepared  from  heart  valves  was  promoted  when  the  material  was 
combined with CBD-HGF (canine pulmonary artery implantation). Similar promotion was observed 
on polytetrafluoroethylene tubes coated with collagen and combined with CBD-HGF (in vitro culture). 
A sheet of collagen preparation (decellularized porcine urinary bladder matrix) could be combined 
with CBD-HGF, and angiogenesis was induced in injured tissues after implantation into mechanically 
injured porcine hearts [93]. 
5.3. Nerve Regeneration 
Fibrin-binding NGF (TG-P-NGF) mixed with fibrin  gel  enhanced  neurite extension from  chick 
embryo dorsal root ganglia (organ culture) by 50% relative to native NGF and by 350% relative to the Int. J. Mol. Sci. 2012, 13  6065 
 
 
fibrin gel alone, in spite of the reduced activity of the fusion construct [25]. Collagen-binding NGF 
(CBD-NGF)  combined  with  a  collagen  membrane  and  implanted  subcutaneously  enhanced  nerve 
growth into the membrane [17]; the CBD-NGF-mediated nerve fiber density was approximately twice 
that observed for native NGF. It also enhanced healing of rabbit dermal ischemic ulcers. 
5.4. Bone Regeneration 
Demineralized  bone  matrix  (DBM)  combined  with  collagen-binding  BMP2  (BMP2-h)  was 
implanted subcutaneously in rats and induced ectopic bone formation [16,94]. BMP2-h-loaded DBM 
was also effective in the repair of rabbit mandibular bone defects, with 10–20% higher efficiency than 
that of native BMP2/DBM. In a rat craniotomy defect model, fibrin-binding BMP2 (TG-pI-BMP2) 
induced 76% more defect healing than native BMP2 [26]. This study was extended to the repair of 
long bones, as assessed by bone bridging. 
6. Concluding Remarks 
Growth factors that are able to bind to biological substances and artificial materials that can hardly 
retain  native  growth  factors  have  been  designed  and  synthesized.  As  a  result,  the  stability  of  the 
resultant molecules was enhanced and the doses applied could be reduced. These considerations are 
also central to the production of biomaterials used as tissue repair scaffolds equipped with additional 
functions. There has been an increase in the number of reports on immobilized growth factors, since 
the effect of immobilized growth factors was first reported [95–101]. Thus, covalently immobilized 
growth  factors  have  now  been  used  effectively.  The  biological  signals  provided  by  immobilized 
growth  factors  last  longer  than  with  soluble  ones.  The  long-lasting  effect  and  the  high  local 
concentration on the surface, induced a significant biological effect on cells. Immobilization has been 
extended  from  organic  materials  to  inorganic  materials  including  metals  and  ceramics.  However, 
chemical immobilization is insufficient for maximizing the efficacy of immobilized growth factors, 
because it is difficult to control their orientation. Therefore, to immobilize growth factors, genetic 
engineering and bioorthogonal chemistry approaches are required. These technologies enable specific 
modifications of growth factors, which can be immobilized at the desired orientations. This regulated 
immobilization enhances biological activity through specific interaction with cognate receptors of cells. 
Considering  recent  progress  in  regenerative  medicine,  binding  growth  factors  have  become 
important molecules in culturing various kinds of stem cells and in constructing tissues. Additional 
properties for clinical use should be developed for binding growth factors, such as good stability in the 
human body and low immunogenicity. 
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